Literature DB >> 20465868

Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users.

Stefan W Toennes1, Johannes G Ramaekers, Eef L Theunissen, Manfred R Moeller, Gerold F Kauert.   

Abstract

Saliva is of continuing interest in detecting the influence of drugs while driving. Commercial tests are currently available where cannabis detectability is a major challenge. The present study aids in the understanding of tetrahydrocannabinol (THC) pharmacokinetics in oral fluid. The oral fluid analyses exhibited no significant differences between 12 occasional users and 12 chronic users smoking a standardized cannabis joint, except for the maximum concentrations in the first samples (occasional users, 397- 6438 ng/g; chronic users 387-71,747 ng/g). THC was detectable in all samples with medians in the last samples (8 h) of 6.3 and 11.3 ng/g in occasional and chronic users, respectively. The elimination half-life in both groups was 1.6 +/- 0.4 h. A series of samples was obtained over a period of 8 h without actual drug use representing a later elimination phase. Of these oral fluid samples, only 4.3% were negative for THC despite positive serum, and 24.1% of serum samples were negative despite positive oral fluid. This confirms that THC is detectable for longer in oral fluid than in serum. The oral fluid-to-serum ratios were 0.3 to 425 (median 16.5) with no difference between chronic and occasional users. The large inter- and intraindividual variability observed precludes a reliable estimation of THC serum concentrations from oral fluid data using this collection device.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465868     DOI: 10.1093/jat/34.4.216

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  18 in total

1.  Cannabinoid disposition in oral fluid after controlled smoked cannabis.

Authors:  Dayong Lee; David M Schwope; Garry Milman; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-01-24       Impact factor: 8.327

2.  Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth.

Authors:  Teresa R Gray; Rina D Eiden; Kenneth E Leonard; Gerard J Connors; Shannon Shisler; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-07-13       Impact factor: 8.327

3.  Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Authors:  Dayong Lee; Erin L Karschner; Garry Milman; Allan J Barnes; Robert S Goodwin; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-11-10       Impact factor: 4.492

4.  Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration.

Authors:  Dayong Lee; Ryan Vandrey; Garry Milman; Mateus Bergamaschi; Damodara R Mendu; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-07-06       Impact factor: 4.142

5.  Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Authors:  Madeleine J Swortwood; Matthew N Newmeyer; Maria Andersson; Osama A Abulseoud; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2016-10-13       Impact factor: 3.345

6.  Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.

Authors:  Sebastien Anizan; Garry Milman; Nathalie Desrosiers; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-08-17       Impact factor: 4.142

7.  Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.

Authors:  Garry Milman; David M Schwope; Eugene W Schwilke; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-29       Impact factor: 8.327

8.  Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.

Authors:  Matthew N Newmeyer; Nathalie A Desrosiers; Dayong Lee; Damodara R Mendu; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-03-20       Impact factor: 3.345

Review 9.  Current knowledge on cannabinoids in oral fluid.

Authors:  Dayong Lee; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2013-08-25       Impact factor: 3.345

10.  Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.

Authors:  Dayong Lee; Ryan Vandrey; Damodara R Mendu; Sebastien Anizan; Garry Milman; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-08-12       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.